Augmentation with antidepressants in schizophrenia treatment: benefit or risk

Mao, Yuejian; Zhang, Mingdao

doi:10.2147/ndt.s62266

Cited by 24 publications

(12 citation statements)

References 132 publications

(130 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the addition of antidepressants to antipsychotics is an evidence-based treatment for negative symptoms in schizophrenia, [63] with the caveat that the inclusion criteria of these studies were not as stringent as in the current review. All definitions of the original authors were accepted without further operationalisation in this previous systematic review [63].…”

Section: Discussionmentioning

confidence: 96%

“…A subgroup analysis of patients with predominant negative symptoms in a meta-analysis on the effects of antidepressants added to antipsychotics revealed a significant positive effect (N = 17, N = 729; SMD − 0.58, CI − 0.94 to − 0.21) [62]. Therefore, the addition of antidepressants to antipsychotics is an evidence-based treatment for negative symptoms in schizophrenia, [63] with the caveat that the inclusion criteria of these studies were not as stringent as in the current review. All definitions of the original authors were accepted without further operationalisation in this previous systematic review [63].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis

Krause

Zhu

Huhn

et al. 2018

Eur Arch Psychiatry Clin Neurosci

169

View full text Add to dashboard Cite

Amisulpride is the only antipsychotic that outperformed placebo in the treatment of predominant negative symptoms, but there was a parallel reduction of depression. Cariprazine was better than risperidone in a large trial that was well-controlled for secondary negative symptoms, but the trial was sponsored by its manufacturer. Future trials should apply scientifically developed definitions such as the deficit syndrome and the persistent negative symptoms concept.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis

Krause

Zhu

Huhn

et al. 2018

Eur Arch Psychiatry Clin Neurosci

169

View full text Add to dashboard Cite

show abstract

“…11). The combination of a secondgeneration or atypical antipsychotic agent with an SSRI has been reported the most popular choice among psychiatrists worldwide [14].…”

Section: Antidepressants Utilisation Pattern Among Schizophrenia Patientsmentioning

confidence: 99%

Drug Prescription Pattern of Psychotropic Drugs Used for the Management of Schizophrenia in a Tertiary Care Speciality Hospital in South Kerala

Dharman

Krishnan

Ravikumar

2021

JPRI

View full text Add to dashboard Cite

An individual affected by psychotic illness is usually a burden to both the society as well as their family in terms of non-productivity. The WHO recognized the significance of mental health and defined it as “a state of complete physical, mental and social well-being”.A psychiatric or psychotropic medication refers to a psychoactive substance administered to exert an effect on the chemical makeup of the brain and nervous system. A hospital based cross sectional observational study was undertaken in the Mental Health Centre, Trivandrum. All psychiatric drugs prescribed was collected with the help of data collection form and anaysed with Excel and SPSS. The study data indicated that highest percentage of drugs used was coming under the classification antipsychotice agents (63.25%), followed by antianxietic agents (21.25%), antiepileptic agents (9.34%), antimania agents (3.07%) and antidepressants (3.07%). Highly prescribed antipsychotic agent was Risperidone (12.93%) followed by haloperidol (11.40%), Promethazine (10.50%).This study was conducted in a govt hospital, so all medicine was free of cost. Due to the poor financial quality of life of psychiatric patients , prescribers were forced to write the hospital avilable medicine to the patients. The main limitation of this study was, it is only a single centered sudy so the result was very limited. So multicentered study is recommended to get a better result to find out the prescribing pattern and pattern of schizophrenia in kerala.

show abstract

“…[13][14][15] Nevertheless, augmentation strategies were associated with a substantial risk of decreased adherence and poor tolerability as a consequence of potential pharmacokinetic interactions and worsening of psychotic symptoms. 16 Therefore, in the light of the mentioned unmet needs, novel treatment strategies, based on more selective receptor activity profiles, became a key area of SCZ research in order to improve the efficacy and tolerability of new compounds. 17 In this regard lumateperone, an investigational drug displaying high-affinity binding to the 5-HT2AR as well to D1 and D2Rs, but with minimal binding affinity for 5-HT2CR, histaminergic and muscarinic receptors, received its first global approval in the USA for the treatment of SCZ in adults, in view of its efficacy with a favorable safety profile.…”

Section: Introductionmentioning

confidence: 99%

Experimental Serotonergic Agents for the Treatment of Schizophrenia

Capuzzi¹,

Caldiroli²,

Ciscato³

et al. 2021

JEP

View full text Add to dashboard Cite

Schizophrenia remains one of the most chronic and highly disabling mental disorder. To date, the pathomechanism of schizophrenia is not fully understood and current treatments are characterized by some limitations. First- and second-generation antipsychotics have shown clinical efficacy in treating positive symptoms, while are poorly effective on both negative symptoms and cognitive deficits. Moreover, they can involve many metabolic and neurological side effects, leading to low therapeutic compliance. Many evidence suggested that serotonin may play a complex role in the neurobiology of schizophrenia. Therefore, new drugs targeting 5-HT receptors (5-HTRs) have become an important area of research in schizophrenia in the hope that treatment efficacy may be improved without inducing side effects observed with currently available antipsychotics. Research using the main database sources was conducted to obtain an overview of preclinical and clinical pharmacological 5-HTR-targeted therapies in patients with schizophrenia. We identified 17 experimental serotonergic agents, under study for their potential use in schizophrenia treatment. Particularly, AVN-211, LuAF-35700 and Brilaroxazine are currently under clinical development. Moreover, some compounds showed some pro-cognitive and antipsychotic-like properties in animal models, while other agents showed contradictory effects in improving symptoms and were removed from the development program. Although some serotonergic drugs seem promising for improving the treatment of schizophrenia, further studies regarding the pathophysiological mechanisms of schizophrenia and novel compounds as well as high-quality trials are necessary in order to improve schizophrenia outcomes.

show abstract

Augmentation with antidepressants in schizophrenia treatment: benefit or risk

Cited by 24 publications

References 132 publications

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis

Drug Prescription Pattern of Psychotropic Drugs Used for the Management of Schizophrenia in a Tertiary Care Speciality Hospital in South Kerala

Experimental Serotonergic Agents for the Treatment of Schizophrenia

Contact Info

Product

Resources

About